# 2025年12月12日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. GLP-1受体激动剂使用与2型糖尿病中癫痫风险的关联

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41370744)
**期刊：** Neurology
**PMID：** 41370744
**DOI：** 10.1212/WNL.0000000000214509

### 第一部分 原文与翻译

**英文原标题：** Association Between GLP-1 Receptor Agonist Use and Epilepsy Risk in Type 2 Diabetes.

> **英文摘要：**
> BACKGROUND AND OBJECTIVES: Individuals with type 2 diabetes mellitus (T2DM) are at an increased risk of developing epilepsy, particularly in later life. While preclinical studies suggest neuroprotective properties of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), real-world comparative effectiveness data remain limited. We aimed to evaluate whether GLP-1 RA use is associated with a lower risk of incident epilepsy compared with dipeptidyl peptidase-4 inhibitor (DPP-4i) use in adults with T2DM.
> 
> METHODS: We conducted a retrospective cohort study using the TriNetX network from 2015 to 2023, including adults aged 18 years or older with T2DM who were new users of either GLP-1 RAs or DPP-4is. Patients with a previous diagnosis of epilepsy or seizure, or those using antiepileptic drugs, were excluded. The primary outcome was incident epilepsy, identified using ICD-10-CM codes. Propensity score matching (1:1) was performed based on demographics, socioeconomic status, body mass index, comorbidities, and baseline medications. Cox proportional hazard models estimated hazard ratios (HRs) with 95% CIs. We also conducted prespecified subgroup and sensitivity analyses to assess the robustness of the findings.
> 
> RESULTS: After matching, 452,766 patients were included (226,383 in each group; mean age 60.5 years; 47.1% female). During follow-up, 1,670 individuals in the GLP-1 RA group and 1,886 in the DPP-4i group developed epilepsy, corresponding to cumulative incidences of 2.35% vs 2.41%. GLP-1 RA use was associated with a significantly lower risk of epilepsy (HR 0.84, 95% CI 0.78-0.90), with protective associations evident at 1 year (HR 0.71, 95% CI 0.62-0.80), 3 years (HR 0.81, 95% CI 0.74-0.88), and 5 years (HR 0.82, 95% CI 0.76-0.88). Among individual agents, semaglutide showed the strongest association (HR 0.68, 95% CI 0.60-0.77). The results were consistent across major subgroups, including both age and sex. Sensitivity analyses excluding patients with overlapping or switching exposure yielded similar findings (HR 0.71, 95% CI 0.64-0.78).
> 
> DISCUSSION: GLP-1 RA therapy was associated with a significantly lower epilepsy risk compared with DPP-4i use in adults with T2DM. These results support the hypothesis that GLP-1 RAs may exert neurologic benefits beyond glycemic control. Limitations include the observational design and potential residual confounding.
> 
> CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that the use of GLP-1 RAs in people with T2DM results in a lower risk of developing epilepsy compared with those treated with DPP-4i.

> **中文摘要：**
> 背景与目的：2型糖尿病（T2DM）患者患癫痫的风险增加，尤其在生命后期更为显著。尽管临床前研究提示胰高糖素样肽-1受体激动剂（GLP-1 RA）具有神经保护特性，但真实世界的比较有效性数据仍然有限。本研究旨在评估，与使用二肽基肽酶-4抑制剂（DPP-4i）的成人T2DM患者相比，GLP-1 RA的使用是否与较低的新发癫痫风险相关。
> 
> 方法：我们基于TriNetX数据库进行了2015年至2023年的回顾性队列研究，纳入年龄≥18岁的T2DM新使用GLP-1 RA或DPP-4i的患者。既往有癫痫或发作诊断者，或已使用抗癫痫药者被排除。主要结局为新发癫痫，通过ICD-10-CM编码识别。基于人口学特征、社会经济状况、体质指数、合并症及基线用药进行1:1倾向评分匹配。采用Cox比例风险模型估算风险比（HR）及95%置信区间（CI）。此外，我们进行了预先设定的亚组与敏感性分析以评估结果的稳健性。
> 
> 结果：匹配后共纳入452,766名患者（每组226,383人；平均年龄60.5岁；女性占47.1%）。随访期间，GLP-1 RA组1,670人、DPP-4i组1,886人发生癫痫，累积发病率分别为2.35%与2.41%。GLP-1 RA使用与显著较低的癫痫风险相关（HR 0.84，95% CI 0.78–0.90），在1年（HR 0.71，95% CI 0.62–0.80）、3年（HR 0.81，95% CI 0.74–0.88）及5年（HR 0.82，95% CI 0.76–0.88）均呈保护效应。在具体药物中，司美格鲁肽的关联最强（HR 0.68，95% CI 0.60–0.77）。结果在主要亚组分析中（包括年龄与性别）保持一致。排除暴露重叠或药物转换者的敏感性分析结果相似（HR 0.71，95% CI 0.64–0.78）。
> 
> 讨论：在成人T2DM患者中，GLP-1 RA治疗较DPP-4i使用显著降低癫痫风险。此结果支持GLP-1 RA可能具有超越血糖调控的神经学益处。研究局限包括观察性设计及潜在的残余混杂。
> 
> 证据分级：本研究提供了III类证据，表明GLP-1 RA的使用可降低T2DM患者相较于DPP-4i治疗者发生癫痫的风险。

### 第二部分 AI 大师评价

该研究利用大型真实世界数据库，比较GLP-1受体激动剂与DPP-4抑制剂在2型糖尿病患者中新发癫痫风险上的差异。通过倾向评分匹配与多重敏感性分析，结果表明GLP-1 RA显著降低癫痫发生风险，尤其以司美格鲁肽效果最强。研究创新之处在于首次大规模量化GLP-1 RA的神经保护潜力，为其在代谢与神经交叉领域提供了临床依据。局限性为观察性设计可能存在残余混杂，需进一步随机对照试验证实。

---

## 2. 产前暴露于抗癫痫药物与先天畸形风险：韩国全国人群为基础的研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41370743)
**期刊：** Neurology
**PMID：** 41370743
**DOI：** 10.1212/WNL.0000000000214350

### 第一部分 原文与翻译

**英文原标题：** Prenatal Exposure to Antiseizure Medications and the Risk of Congenital Anomalies: A Nationwide Population-Based Study in South Korea.

> **英文摘要：**
> BACKGROUND AND OBJECTIVES: Valproate has a well-documented teratogenic risk, whereas lamotrigine and levetiracetam seem relatively safe. However, evidence for other antiseizure medications (ASMs) and specific congenital anomalies remains limited and inconsistent. We aimed to assess the risk of overall and specific congenital anomalies associated with prenatal exposure to individual ASMs.
> 
> METHODS: We conducted a retrospective cohort study using the Korean National Health Insurance Service mother-child linkage database from 2013 to 2021. Pregnant women aged 20-45 years with live births were included. Exposure was defined as the prescription of any ASM during the first trimester. The primary outcome was congenital anomalies in offspring identified by diagnostic codes within 1 year of birth. We estimated the odds ratios (ORs) for overall congenital anomalies, organ system anomalies, and specific congenital anomalies associated with prenatal exposure to ASMs compared with those in the unexposed group. Propensity score fine stratification was used to adjust for potential confounders.
> 
> RESULTS: Among 2,494,958 pregnancies, 5,880 (0.24%) were exposed to ASMs during the first trimester. The mean maternal age at delivery was 32.9 years in the exposed group and 32.4 years in the unexposed group. ASM exposure was associated with an increased risk of overall congenital anomalies (OR 1.26, 95% CI 1.11-1.43). Among monotherapies, valproate had the highest risk (OR 1.46, 95% CI 1.11-1.91), showing a dose-dependent relationship (OR 1.57, 95% CI 1.12-2.19 at ≥500 mg/d). Polytherapy, including valproate, had a higher risk (OR 2.06, 95% CI 1.32-3.20), whereas polytherapy without valproate was not significantly associated with an increased risk (OR 1.26, 95% CI 0.92-1.71). Specific congenital anomalies associated with individual ASMs included congenital hydrocephalus (carbamazepine), atrial septal defects (oxcarbazepine), cleft palate (valproate), hypospadias (levetiracetam), and tetralogy of Fallot and talipes equinovarus (topiramate).
> 
> DISCUSSION: This study revealed that prenatal exposure to valproate increased the risk of congenital anomalies. Although other ASMs, even in polytherapy, did not significantly increase the overall risk of congenital anomalies, carbamazepine, levetiracetam, oxcarbazepine, and topiramate were associated with specific types of congenital anomalies. Given the limited number of cases, these findings warrant further investigation in other populations.
> 
> CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that prenatal exposure to valproic acid increases the risk of overall congenital anomalies while other ASMs, including carbamazepine, levetiracetam, oxcarbazepine, and topiramate, do not increase the risk of overall congenital anomalies.

> **中文摘要：**
> 背景与目的：丙戊酸的致畸风险已有充分证据，而拉莫三嗪和左乙拉西坦则似乎相对安全。然而，对于其他抗癫痫药物（ASMs）及其与特定先天畸形之间关系的证据仍有限且不一致。本研究旨在评估胎儿期暴露于个别ASMs与总体及特定先天畸形风险的关联。
> 
> 方法：我们利用韩国国家健康保险服务的母婴关联数据库，进行了2013年至2021年的回顾性队列研究。纳入20至45岁、有活产记录的孕妇。暴露定义为妊娠第一孕期内开具任何ASM处方。主要结局为出生后1年内通过诊断编码识别出的子代先天畸形。我们计算了胎儿期ASMs暴露与总体先天畸形、器官系统畸形及特定先天畸形风险的比值比（OR），并与未暴露组进行比较。通过倾向评分精细分层校正潜在混杂因素。
> 
> 结果：在2,494,958例妊娠中，有5,880例（0.24%）于第一孕期暴露于ASMs。暴露组平均分娩年龄为32.9岁，未暴露组为32.4岁。ASM暴露与总体先天畸形风险增加相关（OR 1.26，95% CI 1.11–1.43）。在单药治疗中，丙戊酸风险最高（OR 1.46，95% CI 1.11–1.91），且呈剂量依赖性关系（≥500 mg/d时OR 1.57，95% CI 1.12–2.19）。包含丙戊酸的多药治疗风险更高（OR 2.06，95% CI 1.32–3.20），而不含丙戊酸的多药治疗风险未显著增加（OR 1.26，95% CI 0.92–1.71）。与个别ASMs相关的特定先天畸形包括：脑积水（卡马西平）、房间隔缺损（奥卡西平）、腭裂（丙戊酸）、尿道下裂（左乙拉西坦），以及法洛四联症和马蹄内翻足（托吡酯）。
> 
> 讨论：本研究表明，胎儿期暴露于丙戊酸会增加先天畸形风险。尽管其他ASMs即使用于多药联合时也未显著增加总体先天畸形风险，但卡马西平、左乙拉西坦、奥卡西平和托吡酯与特定类型的先天畸形相关。鉴于病例数有限，这些发现需要在其他人群中进一步验证。
> 
> 证据分级：本研究提供III级证据，表明孕期暴露于丙戊酸会增加总体先天畸形风险，而卡马西平、左乙拉西坦、奥卡西平和托吡酯等其他ASMs不会增加总体先天畸形风险。

### 第二部分 AI 大师评价

该研究利用韩国全国健康保险数据库的大样本回顾性队列，系统评估了孕期抗癫痫药物暴露与先天畸形的关系。结果再次确认了丙戊酸的显著致畸风险，且呈剂量依赖性，同时揭示了其他ASMs与特定畸形之间的潜在关联。方法上采用倾向评分精细分层，有助于控制混杂因素，结果具有较高可靠性。研究的创新在于提供了针对多种ASMs的系统性风险评估，但由于部分药物暴露样本较少，统计不确定性仍需在多中心研究中进一步验证。

---

## 3. 功能性癫痫发作管理实践指南执行摘要：美国神经病学学会指南小组报告

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41370742)
**期刊：** Neurology
**PMID：** 41370742
**DOI：** 10.1212/WNL.0000000000214466

### 第一部分 原文与翻译

**英文原标题：** Management of Functional Seizures Practice Guideline Executive Summary: Report of the AAN Guidelines Subcommittee.

> **英文摘要：**
> This guideline provides evidence-based recommendations for clinicians, patients, and other stakeholders on the management of functional seizures. Following a National Academy of Medicine-compliant process, a multidisciplinary panel conducted a systematic review and integrated the findings with the authors' clinical experience to develop recommendations. A systematic review of the available evidence from first published articles to February 25, 2025, identified 12 Class II-III studies. The review found that psychological interventions are possibly effective in increasing the likelihood of achieving freedom from functional seizures, decreasing the frequency of functional seizures, decreasing anxiety, and improving health-related quality of life and psychosocial functioning for individuals with functional seizures. Key recommendations state that, when evaluating patients with seizure-like episodes, clinicians should seek historical and semiological information (including smartphone videos) from both patients and witnesses and may obtain video-EEG of all typical seizure-like episodes where feasible. Clinicians should evaluate patients diagnosed with functional seizures for co-occurring psychiatric disorders and co-occurring epilepsy. Clinicians should adhere to universal standards of care for patients, including speaking respectfully, refraining from unnecessary harm, and avoiding stigmatizing behavior. Clinicians should provide a specific diagnostic label and rationale for the diagnosis, should engage in shared decision making regarding the treatment plan, and should provide continuity of care to individuals diagnosed with functional seizures. When psychological interventions for functional seizures are indicated, clinicians should counsel patients regarding the potential benefits and risks of these interventions and should refer interested and appropriate patients to these interventions for the treatment of functional seizures. Clinicians should involve family, caregivers, or others in the social support network in the psychological treatment of individuals with functional seizures. Clinicians should not prescribe benzodiazepines or antiseizure medications for patients with functional seizures without co-occurring epilepsy or another indication for these medications and should counsel patients regarding the potential risks and lack of evidence of benefit for using these medications for functional seizures. Clinicians should taper off antiseizure medications for patients with functional seizures and without another indication for these medications. The guideline also identifies gaps in the available evidence and outlines potentially clinically impactful avenues for future research.

> **中文摘要：**
> 本指南为临床医生、患者及其他相关利益方提供了关于功能性癫痫发作管理的循证建议。依据符合美国国家医学院标准的流程，多学科小组进行了系统性综述，并结合作者的临床经验以制定建议。从最早发表的研究至2025年2月25日的可用证据系统性回顾共识别出12项Ⅱ级及Ⅲ级研究。综述发现，心理干预可能有效地提高功能性癫痫发作缓解的可能性，减少发作频率，减轻焦虑，并改善患者的健康相关生活质量和社会心理功能。主要建议指出，当评估具有癫痫样发作的患者时，临床医生应从患者及目击者处获取病史和症状学信息（包括智能手机视频），并在可行时获取所有典型癫痫样发作的视频脑电图记录。临床医生应评估被诊断为功能性癫痫发作的患者是否伴有精神障碍或共存的癫痫。临床医生应遵循通用护理标准，包括尊重地与患者交流、避免不必要的伤害及避免污名化行为。临床医生应提供明确的诊断标签及其依据，应与患者共同制定治疗计划，并为被诊断为功能性癫痫发作的个体提供持续性照护。当功能性癫痫发作需要心理干预时，临床医生应向患者说明干预的潜在益处与风险，并将有兴趣且合适的患者转介至相关心理干预。临床医生应鼓励家庭成员、照护者或社会支持网络中的其他人员参与患者的心理治疗。对于无共存癫痫或无其他适应证的功能性癫痫发作患者，临床医生不应开具苯二氮䓬类药物或抗癫痫药物，并应向患者说明这些药物在功能性癫痫发作中的潜在风险及缺乏疗效证据。对于此类患者，应逐渐停用抗癫痫药物。该指南同时指出现有证据的不足，并提出了未来具有潜在临床意义的研究方向。

### 第二部分 AI 大师评价

该实践指南汇总现有证据并结合临床经验，系统性地制定了功能性癫痫发作管理的推荐方案。其方法学遵循国家医学院标准，覆盖诊断、沟通、心理干预及药物管理等关键环节。结果强调心理治疗的潜在疗效，并明确反对不当使用抗癫痫及镇静药物。创新之处在于融入视频EEG和患者自录资料以提升诊断精准度，为未来研究和临床实践提供了可操作框架。局限在于高质量研究数量有限，需更多随机对照试验验证结论。

---

## 4. 教学视频神经影像：原发体感皮层局灶性皮质发育不良引发的叩击诱发性癫痫发作。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41370741)
**期刊：** Neurology
**PMID：** 41370741
**DOI：** 10.1212/WNL.0000000000214512

### 第一部分 原文与翻译

**英文原标题：** Teaching Video NeuroImage: Tapping-Triggered Seizure Secondary to Focal Cortical Dysplasia in the Primary Somatosensory Cortex.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要可用。

### 第二部分 AI 大师评价

该研究以教学性视频神经影像的形式，展示了一例因原发体感皮层局灶性皮质发育不良导致的叩击诱发性癫痫发作病例。此类报告有助于临床医生认识触发特定部位刺激可以诱发癫痫放电的机制。与以往单纯通过EEG或MRI描述不同，视频神经影像提供了更直观的教学价值。虽然缺乏大样本验证，但该病例的罕见性与影像直观性为癫痫病灶定位教学提供了独特视角。

---

速递结束，祝您工作愉快！